Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult : PO HTN 1.25-2.5 mg once daily. Oedema 2.5 mg once daily, up to 5 mg/day after 1 wk if needed.
Dosage Details
Adult: 2.5 mg once daily increased to 5 mg daily after 1 wk if needed.

Adult: 1.25-2.5 mg once daily, alone or in conjunction with other antihypertensives.
May be taken with or without food.
Anuria, severe hepatic impairment.
Special Precautions
Pregnancy, lactation, elderly, renal impairment, fluid or electrolyte imbalance, hyperuricaemia, DM, lupus erythematosus.
Adverse Reactions
Headache, dizziness, weakness, drowsiness, fatigue, agitation, nervousness, anorexia, nausea, vomiting, pain, diarrhoea, constipation, orthostatic hypotension, palpitations, hypokalaemia, hyponatraemia, metabolic alkalosis.
Nausea, vomiting, weakness, GI disorders, electrolyte imbalance. In severe cases, hypotension and respiratory depression. Stomach emptying recommended.
Drug Interactions
Additive effect with other antihypertensive agents and diuretics. Increased chance of hypokalaemia with corticosteroids, corticotropin and amphotericin.
Potentially Fatal: Increased risk of lithium toxicity. Hypokalaemia enhances digitalis toxicity with cardiac gycosides.
Description: Indapamide enhances excretion of sodium, chloride and water by interfering with the transport of sodium ions across the renal tubular epithelium.
Absorption: Rapidly and completely absorbed from the GI tract (oral). Peak plasma levels are achieved within 2-2.5 hr.
Distribution: Widely distributed, preferentially and reversibly bound to erythrocytes.
Metabolism: Extensively metabolised in the liver.
Excretion: Via urine (60-70% as metabolites, 5-7% as unchanged), via faeces (16-23% remaining dose); 14 hr (elimination half-life).
Store at 20-25°C.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Indapamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by
  • Apo-Indapamide
  • Dapalix
  • Indalix
  • Napamide
  • Rinalix
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in